Not Signed In - Acorda Announces Positive Phase 3 Fampridine-SR Study In People With Multiple Sclerosis
Thu, 28 Sep 2006 10:00 AM EST
... Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced positive results from its Phase 3 clinical trial of Fampridine-SR on walking in people with multiple sclerosis (MS). Statistical significance was achieved on all three efficacy criteria defined in the Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA). [click link for full article] ...
Related Topics
- Multiple Sclerosis/ms
- Multiple Sclerosis
- Bupropion SR
- Tuberous Sclerosis
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Lichen Sclerosis
- Multiple Chemical Sensitivity
- Healthy People 2010
- Indomethacin SR
- Verapamil Extended-release
- Interferon Beta-1a Injection (Rebif
- Procainamide ER
- Interferon Beta-1a Injection (Avonex
- Twins, Triplets, Multiple Births
- Multiple System Atrophy
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Tb
email this page
print this page
bookmark this page
feedback on this page
